Helus Pharma Begins Trading on Nasdaq, Advances Therapeutic Innovation in Mental Health
Helus Pharma, originally Cybin Inc., announced that its American Depositary Shares (ADSs) have commenced trading on the Nasdaq Stock Market under the ticker symbol NASDAQ: HELP. The listing marks an important milestone for the company as it seeks to broaden its visibility among investors while advancing its pipeline of novel therapies for mental health and central nervous system disorders.
Focused on Next-Generation Mental Health Therapies
Helus Pharma is developing a portfolio of clinical-stage programs aimed at conditions with significant unmet need, including major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder (PTSD). The company’s approach emphasizes innovative mechanisms of action that leverage advances in neuroscience to improve outcomes for patients who have not responded adequately to existing treatment options.
While Helus’ pipeline comprises multiple assets at various stages of development, the listing underscores the company’s commitment to rigorous clinical evaluation, regulatory progress, and long-term patient impact.
Strategic Rationale for Nasdaq Listing
Listing on Nasdaq provides Helus Pharma with enhanced access to capital markets, broader exposure to U.S. and global investors, and a platform to support future growth. The company said the move will complement ongoing research and development activities and help attract long-term institutional and retail investment interest as it advances therapeutic candidates through clinical milestones.
Executives noted that the added visibility and liquidity associated with Nasdaq trading are expected to support strategic partnerships and collaborations that align with Helus’ mission of addressing critical gaps in mental health care.
Looking Ahead
With trading underway, Helus Pharma will continue to focus on clinical progress, regulatory engagement, and building a differentiated mental health portfolio. Key milestones to watch include upcoming data readouts and regulatory filings that could inform product strategies and long-term value creation.
